

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated Tuesday, December 13, 2022 (the “**Prospectus**”) issued by OrbusNeich Medical Group Holdings Limited (the “**Company**”).

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the Offer Shares. Any investment decision in relation to the Offer Shares should be taken solely in reliance on the information provided in the Prospectus.

This announcement does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of Offer Shares in any jurisdiction in which such offer, solicitation or sales would be unlawful. This announcement is not for release, publication or distribution, directly or indirectly, in or into the United States or any other jurisdiction where such distribution is prohibited by law, nor is this announcement an offer for sale or solicitation to purchase or subscribe for securities in the United States or any other jurisdictions. The Offer Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended from time to time (the “**U.S. Securities Act**”), or any applicable state securities laws, and may not be offered, sold, pledged or transferred within the United States or to, or for the account or benefit of U.S. persons (as defined in Regulation S under the U.S. Securities Act (the “**Regulation S**”)) except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act. The Offer Shares are being offered and sold outside the United States in offshore transactions in accordance with Regulation S. There will be no public offering of the securities of the Company in the United States.

The Hong Kong Offer Shares will be offered to the public in Hong Kong subject to the terms and conditions set out in the Prospectus and the related application form. The Hong Kong Offer Shares will not be offered to any person who is outside Hong Kong and/or not resident in Hong Kong. Potential investors of the Offer Shares should note that the Joint Sponsors and the Overall Coordinators shall be entitled to terminate the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the section headed “Underwriting – Underwriting Arrangements and Expenses – Hong Kong Public Offering – Grounds for Termination” in the Prospectus at any time prior to 8.00 a.m. on the Listing Date.



OrbusNeich Medical Group Holdings Limited
業聚醫療集團控股有限公司

(Incorporated in the Cayman Islands with limited liability)

GLOBAL OFFERING

Number of Offer Shares under the Global Offering	: 54,633,000 Shares
Number of Hong Kong Offer Shares	: 5,464,000 Shares (subject to reallocation)
Number of International Offer Shares	: 49,169,000 Shares (subject to reallocation)
Offer Price	: HK\$8.80 per Share plus brokerage of 1.0%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and the Hong Kong Stock Exchange trading fee of 0.005% (payable in full on application, subject to refund)
Nominal value	: US\$0.0005 per Share
Stock code	: 6929

Joint Sponsors, Overall Coordinators, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers



Overall Coordinator, Joint Global Coordinator, Joint Bookrunner and Joint Lead Manager



Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers



Joint Bookrunners and Joint Lead Managers



Your application through the **White Form eIPO** service or the **CCASS EIPO** service must be for a minimum of 500 Hong Kong Offer Shares and in one of the numbers set out in the table. You are required to pay the amount next to the number you select.

No. of Hong Kong Offer Shares applied for	Amount payable on application <i>HK\$</i>	No. of Hong Kong Offer Shares applied for	Amount payable on application <i>HK\$</i>	No. of Hong Kong Offer Shares applied for	Amount payable on application <i>HK\$</i>	No. of Hong Kong Offer Shares applied for	Amount payable on application <i>HK\$</i>
500	4,444.35	7,000	62,220.83	50,000	444,434.54	400,000	3,555,476.32
1,000	8,888.69	8,000	71,109.53	60,000	533,321.45	450,000	3,999,910.86
1,500	13,333.04	9,000	79,998.22	70,000	622,208.35	500,000	4,444,345.40
2,000	17,777.39	10,000	88,886.91	80,000	711,095.27	600,000	5,333,214.48
2,500	22,221.72	15,000	133,330.36	90,000	799,982.17	700,000	6,222,083.56
3,000	26,666.07	20,000	177,773.81	100,000	888,869.08	800,000	7,110,952.64
3,500	31,110.42	25,000	222,217.27	150,000	1,333,303.62	900,000	7,999,821.72
4,000	35,554.76	30,000	266,660.73	200,000	1,777,738.16	1,000,000	8,888,690.80
4,500	39,999.11	35,000	311,104.18	250,000	2,222,172.70	1,500,000	13,333,036.20
5,000	44,443.46	40,000	355,547.63	300,000	2,666,607.24	2,000,000	17,777,381.60
6,000	53,332.15	45,000	399,991.08	350,000	3,111,041.78	2,732,000 ⁽¹⁾	24,283,903.26

(1) Maximum number of Hong Kong Offer Shares you may apply for.

No application for any other number of the Hong Kong Offer Shares will be considered and any such application is liable to be rejected.

THE LISTING APPLICATION

We have applied to the Hong Kong Stock Exchange for the listing of, and permission to deal in, the Shares in issue, the Shares to be issued pursuant to the Global Offering and the Shares which may be issued under the Pre-IPO Share Option Scheme and Post-IPO Share Option Scheme.

Assuming that the Hong Kong Public Offering becomes unconditional at or before 8:00 a.m. on Friday, December 23, 2022 (Hong Kong time), dealings in the Shares are expected to commence at 9:00 a.m. on Friday, December 23, 2022 (Hong Kong time).

STRUCTURE OF THE GLOBAL OFFERING

The Global Offering comprises:

- the Hong Kong Public Offering of initially 5,464,000 Offer Shares (subject to reallocation) in Hong Kong, representing approximately 10% of the total number of Offer Shares available under the Global Offering, and
- the International Offering of initially 49,169,000 Offer Shares (subject to reallocation), representing approximately 90% of the total number of Offer Shares available under the Global Offering.

The allocation of the Offer Shares between the Hong Kong Public Offering and the International Offering will be subject to reallocation as described in the section headed “Structure of the Global Offering” in the Prospectus.

In particular, subject to the requirements under Practice Note 18 of the Listing Rules and Guidance Letter HKEX-GL91-18, the Overall Coordinators (for themselves and on behalf of the Underwriters) may reallocate the Offer Shares from the International Offering to the Hong Kong Public Offering to satisfy valid applications under the Hong Kong Public Offering. In accordance with Guidance Letter HKEX-GL91-18 issued by the Hong Kong Stock Exchange, if such reallocation is done other than pursuant to the clawback mechanism as described in the section headed “Structure of the Global Offering – The Hong Kong Public Offering – Reallocation and clawback” in the Prospectus, the maximum number of the Offer Shares available under the Hong Kong Public Offering after any such reallocation shall not exceed 10,928,000 Offer Shares, representing 20.0% of the Offer Shares initially available under the Global Offering, and the final Offer Price shall be fixed at HK\$8.80 per Offer Share.

PRICING

The Offer Price is HK\$8.80 per Offer Share, unless otherwise announced as further explained in the section headed “Structure of the Global Offering” in the Prospectus. Applicants for the Offer Shares are required to pay, on application, the Offer Price of HK\$8.80 per Offer Share together with brokerage fee of 1.0%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and the Hong Kong Stock Exchange trading fee of 0.005%.

EXPECTED TIMETABLE

Hong Kong Public Offering commences 9:00 a.m. on
Tuesday, December 13, 2022

Latest time for completing electronic applications under
White Form eIPO service through the designated
website www.eipo.com.hk 11:30 a.m. on
Friday, December 16, 2022

Application lists open 11:45 a.m. on
Friday, December 16, 2022

Latest time for (a) completing payment for **White Form eIPO**
applications by effecting internet banking transfer(s) or
PPS payment transfer(s) and (b) giving **electronic**
application instructions to HKSCC 12:00 noon on
Friday, December 16, 2022

If you are instructing your **broker** or **custodian** who is a CCASS Clearing Participant or a CCASS Custodian Participant to give **electronic application instructions** via CCASS terminals to apply for the Hong Kong Offer Shares on your behalf, you are advised to contact your **broker** or **custodian** for the latest time for giving such instructions which may be different from the latest time as stated above.

Application lists close 12:00 noon on
Friday, December 16, 2022

(1) Announcement of

- the final Offer Price,
- the level of indications of interest in the International Offering,
- the level of applications in the Hong Kong Public Offering,
- basis of allocation of the Hong Kong Offer Shares under the Hong Kong Public Offering,

to be published in the www.hkexnews.hk and the
<https://orbusneich.com> on or before Thursday, December 22, 2022

- (2) Results of allocations in the Hong Kong Public Offering (with successful applicants' identification document numbers, where appropriate) to be available through a variety of channels as described in "How to Apply for Hong Kong Offer Shares – Publication of Results" in the Prospectus from Thursday, December 22, 2022

will be available at www.iporesults.com.hk (alternatively: English <https://www.eipo.com.hk/en/Allotment>; Chinese <https://www.eipo.com.hk/zh-hk/Allotment>) with a "search by ID" function from 8:00 a.m. on Thursday, December 22, 2022 to 12:00 midnight on Wednesday, December 28, 2022

from the allocation results telephone enquiry by calling +852 2862 8555 between 9:00 a.m. and 6:00 p.m. on Thursday, December 22, 2022
Friday, December 23, 2022
Wednesday, December 28, 2022
and Thursday, December 29, 2022

Despatch/collection of Share certificates or deposit of the Share certificates into CCASS in respect of wholly or partially successful applications pursuant to the Hong Kong Public Offering on or before Thursday, December 22, 2022

Despatch/collection of refund cheques and White Form e-Refund payment instructions in respect of wholly or partially successful applications (if applicable) or wholly or partially unsuccessful applications pursuant to the Hong Kong Public Offering on or before. Thursday, December 22, 2022

Dealings in the Shares on the Hong Kong Stock Exchange expected to commence at. 9:00 a.m. on Friday, December 23, 2022

Note: Unless otherwise stated, all times and dates refer to Hong Kong local times and dates.

SETTLEMENT

Subject to the granting of the approval for listing of, and permission to deal in, the Shares on the Hong Kong Stock Exchange and compliance with the stock admission requirements of HKSCC, the Shares will be accepted as eligible securities by HKSCC for deposit, clearance and settlement in CCASS with effect from the date of commencement of dealings in the Shares on the Hong Kong Stock Exchange or such other date as may be determined by HKSCC. Settlement of transactions between participants of the Hong Kong Stock Exchange is required to take place in CCASS on the second settlement day after any trading day. All activities under CCASS are subject to the General Rules of CCASS and CCASS Operational Procedures in effect from time to time. All necessary arrangements have been made to enable the Shares to be admitted into CCASS.

Prospective investors should seek the advice of their stockbrokers or other professional advisers for details of those settlement arrangements and how such arrangements will affect their rights and interests.

ELECTRONIC APPLICATION CHANNELS

White Form eIPO service

You may submit your application through the **White Form eIPO** service through the designated website at www.eipo.com.hk (24 hours daily, except on the last day for applications) from 9:00 a.m. on Tuesday, December 13, 2022 until 11:30 a.m. on Friday, December 16, 2022 and the latest time for completing full payment of application monies in respect of such applications will be 12:00 noon on Friday, December 16, 2022, the last day for applications, or such later date as described in the section headed “How to Apply for Hong Kong Offer Shares – Effect of Bad Weather and Extreme Conditions on the opening and closing of the application lists” in the Prospectus.

CCASS EIPO⁽¹⁾

CCASS Clearing/Custodian Participants can input **electronic application instructions** at the following times on the following dates:

Tuesday, December 13, 2022	– 9:00 a.m. to 8:30 p.m.
Wednesday, December 14, 2022	– 8:00 a.m. to 8:30 p.m.
Thursday, December 15, 2022	– 8:00 a.m. to 8:30 p.m.
Friday, December 16, 2022	– 8:00 a.m. to 12:00 noon

CCASS Investor Participants can input **electronic application instructions** from 9:00 a.m. on Tuesday, December 13, 2022 until 12:00 noon on Friday, December 16, 2022 (24 hours daily, except on Friday, December 16, 2022, the last day for applications).

The latest time for inputting your **electronic application instructions** will be 12:00 noon on Friday, December 16, 2022, the last day for applications, or such later time as described in the section headed “How to Apply for Hong Kong Offer Shares – Effect of Bad Weather and Extreme Conditions on the opening and closing of the application lists” in the Prospectus.

Note:

- (1) The times in this sub-section are subject to change as HKSCC may determine from time to time with prior notification to CCASS Clearing Participants, CCASS Custodian Participants and/or CCASS Investor Participants.

If you are instructing your **broker** or **custodian** who is a CCASS Clearing Participant or a CCASS Custodian Participant to give **electronic application instructions** via CCASS terminals to apply for the Hong Kong Offer Shares on your behalf, you are advised to contact your **broker** or **custodian** for the latest time for giving such instructions which may be different from the latest time as stated above.

The application monies (including the brokerage fees, SFC transaction levy, AFRC transaction levy and the Hong Kong Stock Exchange trading fee) will be held by the receiving bank and on behalf of the Company after the closing of the application lists and the refund monies, if any, will be returned to the applicants without interest on or before Thursday, December 22, 2022.

Please refer to the sections headed “Structure of the Global Offering” and “How to Apply for Hong Kong Offer Shares” of the Prospectus for details of the conditions and procedures of the Hong Kong Public Offering.

Application for the Hong Kong Offer Shares will only be considered on the basis of the terms and conditions set out in the Prospectus, the Green Application Form and the designated website (www.eipo.com.hk) for White Form eIPO.

PUBLICATION OF RESULTS

We expect to announce the final Offer Price, the level of indications of interest in the International Offering, the level of applications in the Hong Kong Public Offering and the basis of allocation of the Hong Kong Offer Shares on Thursday, December 22, 2022 on our website at <https://orbusneich.com> and the website of the Hong Kong Stock Exchange at www.hkexnews.hk.

The results of allocations and the Hong Kong identity card/passport/Hong Kong business registration numbers/certificate of incorporation numbers of successful applicants (where applicable) under the Hong Kong Public Offering will be available through a variety of channels at the times and date and in the manner specified in the section headed “How to Apply for Hong Kong Offer Shares – Publication of Results” in the Prospectus.

If an application is rejected, not accepted or accepted in part only, or if the conditions of the Global Offering are not fulfilled in accordance with “Structure of the Global Offering – Conditions of the Global Offering” in the Prospectus or if any application is revoked, the application monies, or the appropriate portion thereof, together with the related brokerage, SFC transaction levy, AFRC transaction levy and the Hong Kong Stock Exchange trading fee, will be refunded, without interest.

No temporary documents of title will be issued in respect of the Shares and no receipt will be issued for sums paid on application. Share certificates will only become valid at 8:00 a.m. on Friday, December 23, 2022 (Hong Kong time), provided that the Global Offering has become unconditional and the right of termination described in the “Underwriting – Underwriting Arrangements and Expenses – Hong Kong Public Offering – Grounds for Termination” section in the Prospectus has not been exercised.

Assuming the Global Offering becomes unconditional at or before 8:00 a.m. on Friday, December 23, 2022 (Hong Kong time), dealings in the Shares are expected to commence at 9:00 a.m. on Friday, December 23, 2022 (Hong Kong time). The Shares will be traded in board lots of 500 Shares each. The stock code of the Shares is 6929.

This announcement is available for viewing on the website of the Company at <https://orbusneich.com> and the website of the Stock Exchange at www.hkexnews.hk.

By order of the Board
**OrbusNeich Medical Group
Holdings Limited**
David Chien
Chairman

Hong Kong, December 13, 2022

As at the date of this announcement, the Board of Directors comprises Mr. David Chien, Ms. Lau Kwai Ching Denise, Mr. Chen Wing Shing and Mr. Chow Ching Chung John as the executive Directors; Mr. Zhou Yi as the non-executive Director; and Mr. Chan Yip Keung, Ms. Tam Lai Fan Gloria and Mr. Lau Ka Keung, BBS, MH, JP as the independent non-executive Directors.